Skeltved, Nanna
Nordmaj, Mie A.
Berendtsen, Nicolai T.
Dagil, Robert
Stormer, Emilie M. R.
Al-Nakouzi, Nader
Jiang, Ke
Aicher, Alexandra
Heeschen, Christopher
Gustavsson, Tobias
Choudhary, Swati
Gögenur, Ismail
Christensen, Jan P.
Theander, Thor G.
Daugaard, Mads
Salanti, Ali
Nielsen, Morten A.
Funding for this research was provided by:
Novo Nordisk Fonden (NNF21OC0068192)
Novo Nordisk (NNF22OC0076055)
Carlsbergfondet (CF20-0045, CF19-0291)
Kræftens Bekæmpelse (R292-A16782)
Royal Library, Copenhagen University Library
Article History
Received: 29 December 2022
Accepted: 28 March 2023
First Online: 28 April 2023
Declarations
:
: All animal studies were approved by the Animal Experiments Inspectorate in Denmark (P19-117 and P21-119) or the local Animal Care and Use Committee (Shanghai Jiao Tong University Project Approval A-2021-001).
: Not applicable.
: TGT, MD, AS, and MoAN have shares in VAR2 Pharmaceuticals which owns the rights to use rVAR2 for diagnosing and treating cancer. MiAN, TG, and SC are partly employed in VAR2 Pharmaceuticals. All other authors declare no conflicts of interest.